Moderna Past Earnings Performance
Past criteria checks 0/6
Moderna's earnings have been declining at an average annual rate of -10.9%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 23.3% per year.
Key information
-10.9%
Earnings growth rate
-10.9%
EPS growth rate
| Biotechs Industry Growth | 14.8% |
| Revenue growth rate | 23.3% |
| Return on equity | -18.6% |
| Net Margin | -43.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Moderna makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 5,081 | -2,224 | 1,293 | 0 |
| 30 Jun 24 | 5,050 | -5,867 | 1,454 | 0 |
| 31 Mar 24 | 5,153 | -5,968 | 1,518 | 0 |
| 31 Dec 23 | 6,848 | -4,714 | 1,549 | 0 |
| 30 Sep 23 | 9,121 | -3,466 | 1,454 | 0 |
| 30 Jun 23 | 10,654 | 1,207 | 1,290 | 0 |
| 31 Mar 23 | 15,059 | 4,784 | 1,169 | 0 |
| 31 Dec 22 | 19,263 | 8,362 | 1,132 | 0 |
| 30 Sep 22 | 21,390 | 11,765 | 958 | 0 |
| 30 Jun 22 | 22,995 | 14,055 | 848 | 0 |
| 31 Mar 22 | 22,600 | 14,638 | 758 | 0 |
| 31 Dec 21 | 18,471 | 12,202 | 567 | 0 |
| 30 Sep 21 | 11,831 | 7,061 | 445 | 0 |
| 30 Jun 21 | 7,019 | 3,495 | 325 | 0 |
| 31 Mar 21 | 2,732 | 598 | 241 | 0 |
| 31 Dec 20 | 803 | -747 | 188 | 0 |
| 30 Sep 20 | 246 | -597 | 135 | 0 |
| 30 Jun 20 | 106 | -488 | 115 | 0 |
| 31 Mar 20 | 52 | -505 | 106 | 0 |
| 31 Dec 19 | 60 | -514 | 110 | 0 |
| 30 Sep 19 | 82 | -535 | 122 | 0 |
| 30 Jun 19 | 106 | -499 | 112 | 0 |
| 31 Mar 19 | 122 | -459 | 105 | 0 |
| 31 Dec 18 | 135 | -402 | 94 | 0 |
| 30 Sep 18 | 192 | -299 | 72 | 0 |
| 30 Jun 18 | 192 | -280 | 70 | 0 |
| 31 Mar 18 | 199 | -266 | 65 | 0 |
| 31 Dec 17 | 206 | -270 | 65 | 0 |
| 31 Dec 16 | 108 | -230 | 57 | 0 |
Quality Earnings: 1MRNA is currently unprofitable.
Growing Profit Margin: 1MRNA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1MRNA is unprofitable, and losses have increased over the past 5 years at a rate of 10.9% per year.
Accelerating Growth: Unable to compare 1MRNA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1MRNA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 1MRNA has a negative Return on Equity (-18.65%), as it is currently unprofitable.